Navigation Links
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:6/16/2009

- Dosimetry Study Results Show Greater Than 300-Fold More Radiation Delivered to Tumor as Compared to Other Normal Organs -

- All Patients in the First Two Cohorts Have Met or Exceeded the Expected Median Survival Time for Recurrent GBM Patients -

TORONTO and TUSTIN, Calif., June 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for glioblastoma multiforme (GBM), a deadly form of brain cancer. The results reported today from an ongoing dosimetry study at U.S. brain cancer centers show that in patients dosed in the first two cohorts of the study, the concentration of Cotara in brain tumors was on average more than 300-fold higher than in other normal organs. In addition, these patients have all either met or exceeded the expected median survival time of six months for recurrent GBM patients. Cotara is currently being tested in this Phase I dose response and dosimetry trial and in a Phase II clinical trial in recurrent GBM patients.

Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. In this study, lead author Sui Shen, Ph.D., associate professor of radiation oncology at the University of Alabama at Birmingham, and his colleagues assessed the concentration of Cotara in GBM patients' tumors and in their healthy brain tissue, as well as in their thyroid, stomach, heart and bone marrow. He found that
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015  Susan Hedstrom, Executive Director of the ... dedicated to supporting research to advance the understanding ... that FPWR has received the organization,s largest donation ... contributed $1 million in support of the organization,s ... "Our gift signifies our tremendous ...
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... 2015 Patent Offering, The patent’s technology ... or therapeutic imaging within a body lumen (open space). ... having a low cost, single-use disposable illumination and camera ... October 18, 2013 and the patent approval was received ... physician to customize the lighting and magnification of the ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2
... Lixte,Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced ... Stroke (NINDS),National Institutes of Health (NIH) and Lixte ... in many common cancers, that,is a target of ... the treatment,of brain tumors., Dr. John S. ...
... BUDAPEST, Hungary, August 19 ChemAxon, a software,solutions ... 5.1 of their cheminformatics toolkits, Marvin & JChem. ... introduction of IUPAC name import,support for OLE 2 ... Marvin & JChem is a software suite of ...
... WELLESLEY, Mass., Aug. 19 Xceed Molecular, a ... announced that R&D Magazine has selected the company,s ... R&D 100 Award. Called,the Oscars of Invention by ... according to R&D, "a mark of excellence known ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents 2Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents 3ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration 2Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award 2
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... the tiniest organs in the body has shown to provide ... University of Bristol researchers and published in Nature Communications ... The carotid body a small nodule (no larger ... carotid artery appears to be a major culprit in ...
... condition called hypertrophic cardiomyopathy (HCM) found that the risk of ... greatest for those who developed this disease as infants with ... inborn errors of metabolism, a group of rare genetic disorders ... processes are disrupted. The findings will be published ...
... common fungus found living in, and on, many parts of ... humans unless it can breach the body,s immune defences, where ... as an opportunistic pathogen that can colonise and infect individuals ... the Society for General Microbiology,s Autumn Conference, gives us a ...
Cached Biology News:Size really does not matter when it comes to high blood pressure 2Risk factors help predict outcomes for children with rare heart condition 2Research identifies how mouth cells resist Candida infection 2
... is an enzyme that catalyzes the ... maltose, maltotriose, and dextrins. The,level of ... human body is of,clinical significance in ... and diabetes; plant and microbial a-amylases ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
Biology Products: